NIH R01 · 2025
The Role of Egfl6 in Tumor Immunity
Ovarian cancer (OvCa) has an extremely high mortality rate, indicating a clear need for new therapeutic approaches. One such approach is immune checkpoint inhibitor (ICI) therapy. Unfortunately, despite the presence of anti-tumor effector cells in many OvCa patients, ICI therapies have poor response rates in OvCa. One reason for this may large numbers of immunosuppressive myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) present in the OvCa. Both MDSC and TAM negatively regulate immunity in cancer and therapeutic approaches which can disrupt the recruitment/function of these cells can enhance ICI response. A potential therapeutic target to disrupt MDSC/TAM is…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.